LIVIVO - Search results -

Search results

Result 1 - 10 of total 369

Search options

Article ; Online: Thrombosis and Anticoagulation Strategies in Patients with COVID-19 Including Japanese Perspective.

Yamashita, Yugo / Kobayashi, Takao / Mo, Makoto

Journal of atherosclerosis and thrombosis

2023 Volume 30, Issue 4, Page(s) 311–320

Abstract: ... anticoagulation strategies for COVID-19 remain unclear. Considering the status of COVID-19-related thrombosis and ... the risks of thrombosis and bleeding. Latest evidences of COVID-19-related thrombosis and anticoagulation ... of thromboembolic risk have been well known in the pre-COVID-19 era, and the risk of COVID-19-associated thrombosis ...

Abstract	Coronavirus disease 2019 (COVID-19) has become a major health problem worldwide since 2020. Although the main pathophysiology of COVID-19 is a respiratory infectious disease, it could also cause cardiovascular complications, including thrombosis. Thus, anticoagulation therapy has been thought to help prevent thrombosis, leading to improved survival. However, to date, several aspects of the optimal anticoagulation strategies for COVID-19 remain unclear. Considering the status of COVID-19-related thrombosis and some domestic issues in Japan, the optimal anticoagulation strategies for COVID-19 might have to be based on Japanese domestic clinical data considering racial difference. Racial disparities in terms of thromboembolic risk have been well known in the pre-COVID-19 era, and the risk of COVID-19-associated thrombosis depending on race could be an important issue. Considering a potential higher risk of bleeding with anticoagulation therapy in the Asian population, it might be important to maintain a good balance between the risks of thrombosis and bleeding. Latest evidences of COVID-19-related thrombosis and anticoagulation strategies, including some domestic issues in Japan, showed a different status of COVID-19-related thrombosis in Japan from that in Western countries, suggesting the potential benefit of different anticoagulation strategies, specifically for the Japanese population. Although these insights could be useful for the consideration of anticoagulation strategies for the Japanese population, the final decision should be based on balancing the benefits and risks of anticoagulation therapy in each patient.
MeSH term(s)	Humans ; Anticoagulants/adverse effects ; Anticoagulants/therapeutic use ; COVID-19/complications ; East Asian People ; Thrombosis/etiology ; Thrombosis/prevention & control ; Thrombosis/drug therapy
Chemical Substances	Anticoagulants
Language	English
Publishing date	2023-02-15
Publishing country	Japan
Document type	Journal Article
ZDB-ID	2011474-6
ISSN	1880-3873 ; 1340-3478
ISSN (online)	1880-3873
ISSN	1340-3478
DOI	10.5551/jat.RV22002
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5192: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Thrombosis and anticoagulation in COVID-19.

Ramos, Roberta Pulcheri / Ota-Arakaki, Jaquelina Sonoe

Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia

2020 Volume 46, Issue 4, Page(s) e20200317

MeSH term(s)	Anticoagulants/therapeutic use ; Betacoronavirus ; COVID-19 ; Coronavirus Infections/complications ; Humans ; Pandemics ; Pneumonia, Viral/complications ; SARS-CoV-2 ; Thrombosis/complications ; Thrombosis/drug therapy
Chemical Substances	Anticoagulants
Keywords	covid19
Language	Portuguese
Publishing date	2020-07-20
Publishing country	Brazil
Document type	Journal Article
ZDB-ID	2223157-2
ISSN	1806-3756 ; 1806-3713
ISSN (online)	1806-3756
ISSN	1806-3713
DOI	10.36416/1806-3756/e20200317
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: COVID-19 and Its Implications for Thrombosis and Anticoagulation.

Berkman, Samuel A / Tapson, Victor F

Seminars in respiratory and critical care medicine

2021 Volume 42, Issue 2, Page(s) 316–326

Abstract: ... even therapeutic anticoagulation, are features of novel coronavirus disease 2019 (COVID-19 ... coagulopathy. It seems well established at this time that a COVID-19 patient deemed sick enough to be ... anticoagulation without a measurable thromboembolic event and how should that anticoagulation be monitored ...

Abstract	Venous thromboembolism, occlusion of dialysis catheters, circuit thrombosis in extracorporeal membrane oxygenation (ECMO) devices, acute limb ischemia, and isolated strokes, all in the face of prophylactic and even therapeutic anticoagulation, are features of novel coronavirus disease 2019 (COVID-19) coagulopathy. It seems well established at this time that a COVID-19 patient deemed sick enough to be hospitalized, should receive at least prophylactic dose anticoagulation. However, should some hospitalized patients have dosage escalation to intermediate dose? Should some be considered for full-dose anticoagulation without a measurable thromboembolic event and how should that anticoagulation be monitored? Should patients receive postdischarge anticoagulation and with what medication and for how long? What thrombotic issues are related to the various medications being used to treat this coagulopathy? Is antiphospholipid antibody part of this syndrome? What is the significance of isolated ischemic stroke and limb ischemia in this disorder and how does this interface with the rest of the clinical and laboratory features of this disorder? The aims of this article are to explore these questions and interpret the available data based on the current evidence.
MeSH term(s)	Adenosine Monophosphate/analogs & derivatives ; Adenosine Monophosphate/therapeutic use ; Alanine/analogs & derivatives ; Alanine/therapeutic use ; Ambulatory Care ; Antibodies, Antiphospholipid/immunology ; Antibodies, Monoclonal, Humanized/therapeutic use ; Anticoagulants/administration & dosage ; Antirheumatic Agents/therapeutic use ; Antiviral Agents/therapeutic use ; COVID-19/blood ; COVID-19/complications ; COVID-19/drug therapy ; COVID-19/immunology ; COVID-19/therapy ; Dose-Response Relationship, Drug ; Drug Combinations ; Duration of Therapy ; Glucocorticoids/therapeutic use ; Hospitalization ; Humans ; Hydroxychloroquine/therapeutic use ; Immunization, Passive ; Lopinavir/therapeutic use ; Ritonavir/therapeutic use ; SARS-CoV-2 ; Thrombolytic Therapy ; Thrombophilia/blood ; Thrombophilia/drug therapy ; Thrombophilia/etiology ; Thrombosis/drug therapy ; Thrombosis/immunology ; Thrombosis/prevention & control ; Venous Thromboembolism/drug therapy ; Venous Thromboembolism/immunology ; Venous Thromboembolism/prevention & control
Chemical Substances	Antibodies, Antiphospholipid ; Antibodies, Monoclonal, Humanized ; Anticoagulants ; Antirheumatic Agents ; Antiviral Agents ; Drug Combinations ; Glucocorticoids ; lopinavir-ritonavir drug combination ; Lopinavir (2494G1JF75) ; remdesivir (3QKI37EEHE) ; Adenosine Monophosphate (415SHH325A) ; Hydroxychloroquine (4QWG6N8QKH) ; tocilizumab (I031V2H011) ; Ritonavir (O3J8G9O825) ; Alanine (OF5P57N2ZX)
Language	English
Publishing date	2021-02-06
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	1183617-9
ISSN	1098-9048 ; 1069-3424
ISSN (online)	1098-9048
ISSN	1069-3424
DOI	10.1055/s-0041-1722992
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1555: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: COVID-19: Thrombosis, thromboinflammation, and anticoagulation considerations.

Levy, Jerrold H / Iba, Toshiaki / Olson, Lyra B / Corey, Kristen M / Ghadimi, Kamrouz / Connors, Jean M

International journal of laboratory hematology

2021 Volume 43 Suppl 1, Page(s) 29–35

Abstract: ... The acute lung injury that initially occurs in COVID-19 results from vascular and endothelial damage from viral injury ... and pathophysiologic responses that produce the COVID-19-associated coagulopathy. Clinicians ... COVID-19 Therapeutic Interventions and Vaccines (ACTIV) studies are important projects that will further ...

Abstract	Vascular endothelial injury is a hallmark of acute infection at both the microvascular and macrovascular levels. The hallmark of SARS-CoV-2 infection is the current COVID-19 clinical sequelae of the pathophysiologic responses of hypercoagulability and thromboinflammation associated with acute infection. The acute lung injury that initially occurs in COVID-19 results from vascular and endothelial damage from viral injury and pathophysiologic responses that produce the COVID-19-associated coagulopathy. Clinicians should continue to focus on the vascular endothelial injury that occurs and evaluate potential therapeutic interventions that may benefit those with new infections during the current pandemic as they may also be of benefit for future pathogens that generate similar thromboinflammatory responses. The current Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) studies are important projects that will further define our management strategies. At the time of writing this report, two mRNA vaccines are now being distributed and will hopefully have a major impact on slowing the global spread and subsequent thromboinflammatory injury we see clinically in critically ill patients.
MeSH term(s)	Anticoagulants/therapeutic use ; COVID-19/blood ; COVID-19/complications ; COVID-19/immunology ; Child ; Disseminated Intravascular Coagulation/etiology ; Endothelium, Vascular/injuries ; Endothelium, Vascular/physiopathology ; Female ; Fibrinolysis ; Forecasting ; Humans ; Lung/blood supply ; Lung/pathology ; Pandemics ; Pregnancy ; Pregnancy Complications, Infectious/blood ; SARS-CoV-2 ; Thromboembolism/etiology ; Thromboembolism/prevention & control ; Thrombophilia/etiology ; Vasculitis/etiology
Chemical Substances	Anticoagulants
Language	English
Publishing date	2021-07-19
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2268590-X
ISSN	1751-553X ; 1751-5521 ; 0141-9854
ISSN (online)	1751-553X
ISSN	1751-5521 ; 0141-9854
DOI	10.1111/ijlh.13500
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1499: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Pulmonary Thrombosis despite Therapeutic Anticoagulation in COVID-19 Pneumonia: A Case Report and Literature Review.

Niculae, Cristian-Mihail / Gorea, Maria-Evelina / Tirlescu, Laura-Georgiana / Constantin, Rares-Alexandru / Moroti, Ruxandra / Hristea, Adriana

Viruses

2023 Volume 15, Issue 7

Abstract: The rate of thrombotic complications in COVID-19 patients is high and could be associated ... regimen, and the risk factor identified was severe COVID-19 pneumonia and a stay in an intensive care unit ... on anticoagulant treatment. We present the case of a patient with severe COVID-19 pneumonia, without traditional ...

Abstract	The rate of thrombotic complications in COVID-19 patients is high and could be associated with the risk of unfavourable outcomes. Moreover, pulmonary thrombotic events can occur even in patients already on anticoagulant treatment. We present the case of a patient with severe COVID-19 pneumonia, without traditional risk factors for thrombosis, who developed massive pulmonary thrombosis (PT) despite therapeutic anticoagulation. The diagnosis was challenging, and the case raised concerns about the protective role of conventional anticoagulant treatment in COVID-19 pneumonia. Thus, we searched for literature reports on COVID-19 patients who developed PT despite being under anticoagulation therapy. We identified 13 cohort studies including 4058 patients of which 346 (8.5%) developed PT and nine case reports/series enrolling 14 patients. Four cohorts were further analysed, which reported data on risk factors for thrombosis, outcomes and biological characteristics. We found that there were no differences between patients with and without PT regarding the classical risk factors for thrombosis. PT occurred regardless of the anticoagulation regimen, and the risk factor identified was severe COVID-19 pneumonia and a stay in an intensive care unit (ICU). Pulmonary thrombotic events in patients with COVID-19 are rather inflammation-related than correlated with traditional thromboembolic risk factors, and the therapeutic approach must take into consideration this aspect.
MeSH term(s)	Humans ; COVID-19/complications ; Venous Thrombosis/complications ; Blood Coagulation ; Thrombosis/etiology ; Thrombosis/chemically induced ; Anticoagulants/adverse effects
Chemical Substances	Anticoagulants
Language	English
Publishing date	2023-07-12
Publishing country	Switzerland
Document type	Case Reports ; Journal Article ; Review
ZDB-ID	2516098-9
ISSN	1999-4915 ; 1999-4915
ISSN (online)	1999-4915
ISSN	1999-4915
DOI	10.3390/v15071535
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: COVID-19 and its implications for thrombosis and anticoagulation.

Connors, Jean M / Levy, Jerrold H

Blood

2020 Volume 135, Issue 23, Page(s) 2033–2040

Abstract: ... immunity to COVID-19 has resulted in large numbers of infected patients across the globe and uncertainty ... including the measurement of D-dimer and fibrinogen levels, is suggested. COVID-19-associated coagulopathy ... Severe acute respiratory syndrome coronavirus 2, coronavirus disease 2019 (COVID-19)-induced ...

Abstract	Severe acute respiratory syndrome coronavirus 2, coronavirus disease 2019 (COVID-19)-induced infection can be associated with a coagulopathy, findings consistent with infection-induced inflammatory changes as observed in patients with disseminated intravascular coagulopathy (DIC). The lack of prior immunity to COVID-19 has resulted in large numbers of infected patients across the globe and uncertainty regarding management of the complications that arise in the course of this viral illness. The lungs are the target organ for COVID-19; patients develop acute lung injury that can progress to respiratory failure, although multiorgan failure can also occur. The initial coagulopathy of COVID-19 presents with prominent elevation of D-dimer and fibrin/fibrinogen-degradation products, whereas abnormalities in prothrombin time, partial thromboplastin time, and platelet counts are relatively uncommon in initial presentations. Coagulation test screening, including the measurement of D-dimer and fibrinogen levels, is suggested. COVID-19-associated coagulopathy should be managed as it would be for any critically ill patient, following the established practice of using thromboembolic prophylaxis for critically ill hospitalized patients, and standard supportive care measures for those with sepsis-induced coagulopathy or DIC. Although D-dimer, sepsis physiology, and consumptive coagulopathy are indicators of mortality, current data do not suggest the use of full-intensity anticoagulation doses unless otherwise clinically indicated. Even though there is an associated coagulopathy with COVID-19, bleeding manifestations, even in those with DIC, have not been reported. If bleeding does occur, standard guidelines for the management of DIC and bleeding should be followed.
MeSH term(s)	Anticoagulants/therapeutic use ; Betacoronavirus/isolation & purification ; Blood Coagulation/drug effects ; COVID-19 ; Coronavirus Infections/blood ; Coronavirus Infections/complications ; Fibrin Fibrinogen Degradation Products/analysis ; Humans ; Pandemics ; Pneumonia, Viral/blood ; Pneumonia, Viral/complications ; SARS-CoV-2 ; Thrombosis/blood ; Thrombosis/drug therapy ; Thrombosis/etiology ; Thrombosis/prevention & control ; Venous Thromboembolism/blood ; Venous Thromboembolism/drug therapy ; Venous Thromboembolism/etiology ; Venous Thromboembolism/prevention & control
Chemical Substances	Anticoagulants ; Fibrin Fibrinogen Degradation Products ; fibrin fragment D
Keywords	covid19
Language	English
Publishing date	2020-04-21
Publishing country	United States
Document type	Journal Article
ZDB-ID	80069-7
ISSN	1528-0020 ; 0006-4971
ISSN (online)	1528-0020
ISSN	0006-4971
DOI	10.1182/blood.2020006000
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.140: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 364: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Prophylactic Anticoagulation and Thrombosis in Hospitalized Patients with Clinically Stable COVID-19 at Admission: From the Practice-Based Observational Study.

Annals of vascular diseases

2023 Volume 17, Issue 1, Page(s) 1–8

Abstract: Objectives: ...

Abstract	Objectives:
Language	English
Publishing date	2023-11-28
Publishing country	Japan
Document type	Journal Article
ZDB-ID	2394256-3
ISSN	1881-6428 ; 1881-641X
ISSN (online)	1881-6428
ISSN	1881-641X
DOI	10.3400/avd.oa.23-00031
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Thrombosis and anticoagulation in COVID-19

Ramos, Roberta Pulcheri / Ota-Arakaki, Jaquelina Sonoe

Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia

Keywords	covid19
Publisher	WHO
Document type	Article
Note	WHO #Covidence: #665195
Database	COVID19

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Book ; Online: Thrombosis and anticoagulation in COVID-19

Ramos, Roberta Pulcheri / Ota-Arakaki, Jaquelina Sonoe

Jornal Brasileiro de Pneumologia v.46 n.4 2020

2020

Keywords	covid19
Language	English
Publishing date	2020-01-01
Publisher	Sociedade Brasileira de Pneumologia e Tisiologia
Publishing country	br
Document type	Book ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: COVID-19 and Its Implications for Thrombosis and Anticoagulation

Berkman, Samuel A. / Tapson, Victor F.

Seminars in Respiratory and Critical Care Medicine

(The Diagnosis and Management of Acute Pulmonary Embolism in 2021: Evolving Strategies)

2021 Volume 42, Issue 02, Page(s) 316–326

Series title	The Diagnosis and Management of Acute Pulmonary Embolism in 2021: Evolving Strategies
Abstract	Venous thromboembolism, occlusion of dialysis catheters, circuit thrombosis in extracorporeal membrane oxygenation (ECMO) devices, acute limb ischemia, and isolated strokes, all in the face of prophylactic and even therapeutic anticoagulation, are features of novel coronavirus disease 2019 (COVID-19) coagulopathy. It seems well established at this time that a COVID-19 patient deemed sick enough to be hospitalized, should receive at least prophylactic dose anticoagulation. However, should some hospitalized patients have dosage escalation to intermediate dose? Should some be considered for full-dose anticoagulation without a measurable thromboembolic event and how should that anticoagulation be monitored? Should patients receive postdischarge anticoagulation and with what medication and for how long? What thrombotic issues are related to the various medications being used to treat this coagulopathy? Is antiphospholipid antibody part of this syndrome? What is the significance of isolated ischemic stroke and limb ischemia in this disorder and how does this interface with the rest of the clinical and laboratory features of this disorder? The aims of this article are to explore these questions and interpret the available data based on the current evidence.
Keywords	COVID-19 ; SARS-CoV2 ; thrombosis ; deep venous thrombosis ; pulmonary embolism ; anticoagulation ; inflammation ; hypercoagulability ; prothrombotic
Language	English
Publishing date	2021-02-06
Publisher	Thieme Medical Publishers, Inc.
Publishing place	Stuttgart ; New York
Document type	Article
ZDB-ID	1183617-9
ISSN	1098-9048 ; 1069-3424
ISSN (online)	1098-9048
ISSN	1069-3424
DOI	10.1055/s-0041-1722992
Database	Thieme publisher's database

In stock of ZB MED Cologne/Königswinter

Zs.A 1555: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito